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Abstract
Background: The aim of this study was to evaluate the effect of topical fibrin glue applied externally to
all anastomoses after a pancreaticoduodenectomy (PD) on drain lipase levels, anastomotic leaks, com-
plication rates and length of hospital stay.
Methods: A standardized non-pylorus preserving PD was performed with or without fibrin glue applied
to each anastomosis.
Results: Fifty-seven patients were randomized: 32 with and 25 without TISSEEL. There were no statis-
tical differences in each group with respect to drain lipase levels (high 40% versus 43%, P = 0.794),
complications including gastric or biliary leaks (24% versus 28%, P = 1.00), wound infection (16% versus
9%, P = 0.28) and a Clavien score of 3 or more (16% versus 25%, P = 0.757) or hospital stay (12 versus
17 days, P = 0.777). Most patients with elevated drain lipase levels had an unaltered clinical course not
predictive of adverse outcomes. However, the operative finding of a soft pancreas (27 out of 57 patients)
was associated with post-operative complications (P = 0.002). There were no peri-operative deaths.
Conclusions:
1 Fibrin glue application to all anastomoses does not alter drain lipase levels.
2 Drain lipase levels are not a significant surrogate marker for clinically significant anastomotic leaks or
complications.
3 Fibrin glue application did not reduce the incidence of an anastomotic leak or complications.
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Introduction
Although peri-operative mortality associated with a pancreati-
coduodenectomy (PD) has improved significantly over the years
(0–3%),1,2 a pancreatic anastomotic leak remains a major compli-
cation after a pancreatic resection.3–5 A pancreatic fistula is the
sequel to further complications such as wound infection, an intra-
abdominal abscess and sepsis. Several manoeuvres have been
employed in attempt to reduce the rates of pancreatic fistulae.
The three main interventions trialled have been: variations of
the pancreatic anastomosis; the use of long-acting somatostatin
analogues such as octreotide; and the use of fibrin glue sealants.
Numerous randomized controlled trials were conducted with the
first two interventions, the majority failing to provide a statistical
difference in reducing rates of pancreatic fistulae or mortality.6
In contrast, the use of fibrin glue sealant about the pancreatic
anastomosis after PD alone has only been performed in only one
randomized trial. Similarly, the authors are not aware of any
randomized trials using fibrin glue about all of the anastomoses
in PD. The role of drain lipase as opposed to drain amylase in this
setting has also not been defined.
TISSEEL (Hemacure Corp., Sarasota, FL, USA; Baxter Health
Care Corp., Glendale, CA, USA) is an adhesive fibrin glue
sealant that consists mainly of human fibrinogen and thrombin
marketed for use in both haemostasis and tissue sealing. Several
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previous non-randomized studies have suggested that the inci-
dence of a fistula decreases after a pancreatic resection with
the application of fibrin glue.7–9 Two recent non-randomized
studies have suggested that the combination of fibrin glue and
polyglicolic acid may similarly reduce the risk of a pancreatic
fistula for patients undergoing a PD.10,11 A prospective rand-
omized multicentre study that applied intraductal fibrin glue
to patients after a PD or a distal pancreatectomy showed no
difference in the rates or severity of pancreatic fistulae or
intra-abdominal complications.
Only one randomized controlled trial that applied topical fibrin
glue about the pancreatic anastomosis specifically after PD has
been reported.12 This excellent trial in a high-volume centre
showed no significant differences in the rates of pancreatic fistulae
or complications among 125 patients with ‘high-risk’ pancreatic
anastomoses (soft or medium texture pancreas and small
pancreatic duct).
Furthermore, the use of TISSEEL to reduce the incidence of a
gastrointestinal anastomotic leak in major visceral surgery has
been trialled in non-randomized trials, some with positive
results.13 No randomized trial of its use in PD about all of the
anastomoses in PD has previously been performed.
Lipase may be found in lingual, intestinal, hepatic or pancreatic
secretions. Hence a drain lipase elevation may reflect a leak from
any of the anastomoses after a PD (pancreatic, biliary or gastric).
Pancreatic lipase activity requires the presence of another enzyme
colipase. Most commercial lipase assays try to favour specificity
for pancreatic lipase by adding bile acids and colipase to partially
inhibit other lipases. In spite of this methodology, lipase on
commercial testing is still present in sputum, gastric and biliary
secretions.
The aim of this study was therefore to evaluate the effect of
topical application of fibrin glue applied to all anastomoses after a
PD on the drain lipase level, anastomotic leak, complication rates
and length of hospital stay in a medium volume centre.
Methods
Surgical technique
All operations were conducted by a single surgeon (I.M.).A stand-
ard non-pylorus preserving PD was performed using the same
anastomotic technique. An end-to-side pancreatico-jejunostomy
was fashioned in two layers using six interrupted 3/0 monocryl
transpancreatic U-sutures to the anterior and posterior serosal
layers of the jejunum as first described by Blumgart14 with 6–10
interrupted 5/0 monocryl pancreatic duct to mucosa sutures. A
hepaticojejunostomy was fashioned using a running 5/0 monoc-
ryl, with a loop gastroenterostomy and a side-to-side jejunojeju-
nostomy constructed using an EndoGIA (Covidian, Mansfield,
MA, USA) stapling device, 60 ¥ 3.5 mm. No feeding tubes were
placed. Peri-operative intravenous (i.v.) pantoperazole 40 mg
daily and subcutaneous octreotide 100 mg 8 hourly for 8–10 days
was utilized.
Randomization criteria
Pre-operative informed consent was obtained from each patient
with randomization occurring during the operation using a coin
toss performed by a theatre nurse (‘Tails for TISSEEL’). At the end
of the procedure, after a thorough lavage, patients randomized to
receive fibrin glue sealant had TISSEEL applied topically through a
double-barrel syringe connected to aY-shaped catheter circumfer-
entially to ensure all four anastomoses received a thin covering layer
(4–10 ml in total required). TISSEEL was not applied into the
pancreatic duct. The randomisation flow chart is shown in Fig. 1.
Post-operative management
Two perianastomotic 19-Fg Blake drains were placed and removed
on the third post-operative day regardless of the drain lipase level
unless the effluent was bile or enteric stained or turbid.
Nasogastric tubes were removed in the first post-operative day
and i.v. erythromycin 50–150 mg 8 hourly commenced on days
3–8 in most patients. Post-operative assessment included meas-
urement of drain and serum lipase from the third day. Creon forte
was given to supplement meals on discharge.
Data collection
Patient trial entry data were collected prospectively and outcomes
assessed retrospectively. Data were collected by single non-blinded
medical researcher.
Study end points
The primary study end points consisted of drain lipase levels,
pancreatic fistulae, anastomotic leak, all complications, length of
hospital stay and death. The validated Clavien score was used to
grade post-operative complications.15
A post-operative pancreatic fistula (POPF) was defined as
drainage fluid of the lipase level three times greater than the
normal serum level (>750 u/l), regardless of the volume of drain-
age fluid from day 3 post-operatively. This is the same as for the
international study group definition with the distinction that
lipase levels were tested rather than amylase levels.4 Grading into
A, B or C was also used as per the international definition.
The effect of fibrin glue on lipase drain levels has not previously
been reported. The sample size of this binary outcome superiority
trial was based on the premise that an elevated day 3 drain lipase
would fall from 40% to 8% in the treatment group at a signifi-
cance level of 5% and a power of 80%. A total of 54 patients were
required with 27 in each group to meet this criteria. Statistical
analyses were performed in R [R Development Core Team (2011),
R: A language and environment for statistical computing. R Foun-
dation for Statistical Computing, Vienna, Austria]. Comparisons
between groups were made using Wilcoxon’s rank sum test in the
case of continuous variables and Fisher’s exact test in the case of
categorical variables. All P-values were two-sided and we used a
statistical significance level of 0.05.
Statistical analyses
Statistical analyses were performed in R (R Development Core
Team). Comparisons between groups weremade usingWilcoxon’s
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rank-sum test in the case of numerical variables and Fisher’s exact
test in the case of categorical variables. All P-values are two sided
with a statistical significance level of 0.05.
Results
Patient population
The patients’ demographic data and pre-operative risk factors
associated with PD morbidity are shown in Table 1. These
patients were randomized with 25 patients in the TISSEEL group
and 32 patients in the control group. There were no significant
differences between the groups in terms of gender and pre-
operative factors except for age. The mean patient age was 67.0
7.9 years in the TISSEEL group and 60.5  9.7 in the control
group (P = 0.017).
There were no significant differences between the groups in
terms of pancreatic texture, pancreatic duct diameter or operation
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Table 1 Patient characteristics and preoperative factors
Patient characteristics TISSEEL (N = 25) No TISSEEL (N = 32) P-value
n (%) n (%)
Age (year), mean  SD, median 67.0  7.9, 67 60.5  9.7, 62 0.017
Male gender 10 (40.0%) 19 (59.4%) 0.186
Smoking history 5 (20.0%) 9 (28.1%) 0.548
Alcohol history 3 (12.0%) 8 (25.0%) 0.315
Pre-operative factors
Jaundice 11 (44.0%) 21 (65.6%) 0.117
Weight loss 13 (52.0%) 16 (50.0%) 1.000
Diabetes mellitusa 4 (16.0%) 6 (18.8%) 1.000
Peripheral vascular disease 0 (0) 4 (12.5%) 0.123
Pancreatitis 2 (8.0%) 4 (12.5%) 0.686
aTISSEEL, N = 24.
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times (Table 2). The histopathological findings are shown in
Table 3. Fifteen patients (60%) in TISSEEL group had a soft pan-
creas compared with 17 patients (53.1%) in the control group.
Complications
Post-operative complications and course are shown in Table 4.
There were no deaths with 44% of all patients experiencing one or
more post-operative complication (48% in the TISSEEL and 41%
the control group). The most common post-operative complica-
tion was POPF, followed by delayed gastric emptying and wound
infection. There were no significant differences in post-operative
complications and length of hospital stay (TISSEEL group: mean
= 14.1  12.7 days, median = 11.0 days; control group: mean =
17.4  17.5 days, median = 10.0 days). TISSEEL application
did not alter morbidity rates using a Clavien score of 3 or 4
(P = 0.757).
Pancreatic fistula
The overall incidence of a pancreatic fistula was 42% (40%
TISSEEL and 44% the control group). The mean post-operative
hospital stay for patients with a pancreatic fistula was 14.1  6.9
days (median = 13.0), whereas the mean post-operative hospital
stay for patients without a pancreatic fistula was 19.5 14.6 days
(median = 12.0). The reason was that of the twenty-four patients
with POPF only two had an altered clinical course, one requiring
percutaneous drainage and the other requiring reoperation
(Grades A 22, B 1, C 1). Pancreatic texture was associated with a
pancreatic fistula (P = 0.002) but was not associated with elevated
morbidity as per the Clavien scores of 3 or 4. The results suggest
that a Clavien score of 3 or 4 is more likely for patients with a high
drain lipase. However, the difference in percentages with a high
Clavien score failed to achieve statistical significance (P = 0.052).
This may be because of the relatively small sample size.
Discussion
POPF has previously been associated with patients found to have
a soft texture of the pancreas.12 This finding was significantly
supported in this study.We defined POPF as per the international
study group definition4 (drain fluid of any volume with an
elevated amylase level three times the serum level from the third
postoperative day) with the exception that lipase was used instead
of amylase. The role of lipase has previously been reported as
having a sensitivity of 93% and specificity of 77% for grades B or
C POPF at a threshold level in the drain of 1000 units/l or four
Table 2 Intra-operative parameters
Variable TISSEEL No TISSEEL P-value
(N = 25) (N = 32)
Texture of pancreas 0.936
Soft 15 (60.0%) 17 (53.1%)
Intermediate 4 (16.0%) 6 (18.8%)
Firm 6 (24.0%) 9 (28.1%)
Width of pancreatic duct (mm) 4.4  1.8, 4.0 3.9  1.5, 3.5 0.154
Operation
Surgical time (h:min)a 3:14  0:56, 3:00 3:20  0:45, 3:25 0.514
Blood loss (ml)b 495.0  280.0, 425.0 581.7  329.4, 450 0.584
Blood transfusion (ml)b 0  0, 0 0  0, 0 NA
aTISSEEL group, N = 21; No TISSEEL, N = 30, mean and median.
bTISSEEL group, N = 20; No TISSEEL, N = 30, mean and median.
NA, not applicable.
Data are presented as n (%) or mean  SD, median.
Table 3 Histopathological findings
Patient characteristics TISSEEL
(n = 25)
No TISSEEL
(n = 32)
Pancreas
Pancreatic adenocarcinoma 8 (32%) 15 (46.8%)
Intraductal papillary mucinous
neoplasm
1 (4%) 2 (6.3%)
Mucinous cystic adenocarcinoma 0 1 (3.1%)
Neuroendocrine carcinoma 1 (4%) 1 (3.1%)
Serous cystadenoma 2 (8%) 1 (3.1%)
Chronic pancreatitis 2 (8%) 0
Autoimmune pancreatitis 1 (4%) 1 (3.1%)
Ampullary adenocarcinoma/adenoma 4 (16%) 7 (21.8%)
Bile duct
Cholangiocarcinoma 2 (8%) 1 (3.1%)
Fibroinflammatory 1 (4%) 0
Duodenum
Duodenal adenocarcinoma 1 (4%) 2 (6.3%)
Tubulovillous adenoma 1 (4%) 1 (3.1%)
Others
Colonic adenocarcinoma invading
pancreas
1 (4%) 0
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times the normal serum level.16 Their study recommends that a
drain lipase level of four times the serum level might be a more
appropriate cut-off to define POPF. Our study supported this
finding as we found a high proportion of patients with lipase-rich
drain fluid more than three times the serum level (42%, 24 of 59
patients) had an unaltered clinical course (grade A POPF 22 of 24
patients).
In the present series only two patients with POPF required
some form of intervention: one grade B requiring percutaneous
drainage only and the other grade C requiring re-operation at day
7 with a normal drain lipase level on the third post-operative day.
The weaknesses of this study were the small sample size and the
method of randomization.As we did not find any trend suggesting
a reduction in lipase-rich drain effluent in the TISSEEL group it
appears unlikely that a larger study would have altered the final
results. Using a coin toss for randomization may result in imbal-
anced sample sizes, as occurred in this study. Furthermore, base-
line characteristics may be imbalanced. We found a difference in
age in the two groups (Table 1); however, all other covariates were
similar. Age was not predictive of adverse outcome or POPF rates
in this study.
This study was unique in its methodology as the fibrin glue was
applied to all the reconstructive PD anastomoses. Theoretically
gastric, biliary and pancreatic lipase will follow the intestinal
lumen and appear in the drain effluent as a surrogate marker to
aid in the diagnosis of any leaking anastomosis. However, this was
not born out in this study as 9 out of 13 reoperations were in fact
for leaking biliary or gastric anastomoses. The biliary leaks were
early (first 3 days) and self evident with bile in the drain effluent
whereas the gastric leaks were delayed (days 6–16) and as a con-
sequence of gastroparesis or incomplete intestinal obstruction.
Thus it appears that drain lipase was not a useful or practical
surrogate marker for either intestinal or pancreatic anastomotic
leak in this series.
In summary, fibrin glue application to all anastomoses did not
alter drain lipase levels. It was found that drain lipase levels were
not a useful surrogate marker for clinically significant anasto-
motic leaks or complications. It appears that high drain lipase
levels as per the international classification of three times the
serum level for POPF as stated for amylase, is not uncommon post
PD and in themajority of cases the clinical outcome was unaltered
(Grade A POPF).
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